Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654057 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CYP1A2HSD17B10KMT2APOLB | |
| SCHEMBL1901172 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CYP1A2HSD17B10KMT2APOLB | |
| SCHEMBL4047674 | 0.86 | KMT2A (0.76) | ALDH1A1CYP1A2HSD17B10KMT2ATP53 | |
| SCHEMBL8532903 | 0.85 | ALDH1A1 (0.67) | ALDH1A1CYP1A2HSD17B10KMT2APOLB | |
| SCHEMBL5458028 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1HSD17B10KMT2APOLBRAB9A | |
| SCHEMBL1884508 | 0.84 | ALDH1A1 (0.73) | ALDH1A1CYP1A2KMT2ARAB9ALMNA | |
| SCHEMBL1303329 | 0.81 | ALDH1A1 (0.72) | ALDH1A1CYP1A2HSD17B10KMT2APOLB | |
| SCHEMBL20057531 | 0.81 | CYP1A2 (0.67) | ALDH1A1CYP1A2HSD17B10KMT2ATP53 | |
| SCHEMBL11877054 | 0.81 | LMNA (0.74) | ALDH1A1CYP1A2KMT2APOLBNR4A1 | |
| Hydrochloric Acid SCHEMBL695094 | 0.79 | ALDH1A1 (0.70) | ALDH1A1CYP1A2HSD17B10KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6027577-A | — | — | None | — | — | JP | disclosed |
| CN-114249702-A | N-aryl- [2,4 '-bithiazole ] -2' -amine compound and preparation and application thereof | 沈阳药科大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-101129295-A | 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems | HERAEUS KULZER GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| JP-H0627577-A | SILVER HALIDE EMULSION SENSITIZED WITH HEAVY METAL COMPOUND AND THIOUREA COMPOUND | EASTMAN KODAK CO | 1994-02-04 | — | — | JP | disclosed |
| US-5283168-A | Increased photographic efficiency and sensitivity | EASTMAN KODAK COMPANY (US) | 1994-02-01 | — | — | US | disclosed |
| US-5283168-A | Increased photographic efficiency and sensitivity | EASTMAN KODAK COMPANY (US) | 1994-02-01 | — | — | US | disclosed |
| EP-0568092-A2 | Silver halide emulsion sensitized with a heavy metal compound and a thiourea compound | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1993-11-03 | — | — | EP | disclosed |
| EP-0568092-A2 | Silver halide emulsion sensitized with a heavy metal compound and a thiourea compound | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | ALDH1A1 339/4885CYP1A2 181/4885HSD17B10 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.